» Articles » PMID: 30794895

Drug Repurposing for New, Efficient, Broad Spectrum Antivirals

Overview
Journal Virus Res
Specialty Microbiology
Date 2019 Feb 23
PMID 30794895
Citations 38
Authors
Affiliations
Soon will be listed here.
Abstract

Emerging viruses are a major threat to human health. Recent outbreaks have emphasized the urgent need for new antiviral treatments. For several pathogenic viruses, considerable efforts have focused on vaccine development. However, during epidemics infected individuals need to be treated urgently. High-throughput screening of clinically tested compounds provides a rapid means to identify undiscovered, antiviral functions for well-characterized therapeutics. Repurposed drugs can bypass part of the early cost and time needed for validation and authorization. In this review we describe recent efforts to find broad spectrum antivirals through drug repurposing. We have chosen several candidates and propose strategies to understand their mechanism of action and to determine how resistance to antivirals develops in infected cells.

Citing Articles

In vitro synergistic antiviral activity of repurposed drugs against enterovirus 71.

Jitobaom K, Boonarkart C, Thongon S, Sirihongthong T, Sornwong A, Auewarakul P Arch Virol. 2024; 169(8):169.

PMID: 39078431 DOI: 10.1007/s00705-024-06097-1.


A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.

Sharun K, Tiwari R, Yatoo M, Natesan S, Megawati D, Singh K Narra J. 2024; 2(3):e92.

PMID: 38449903 PMC: 10914132. DOI: 10.52225/narra.v2i3.92.


Investigation of antiviral substances in Covid 19 by Molecular Docking: In Silico Study.

Oner E, Demirhan I, Miraloglu M, Yalin S, Belge Kurutas E Afr Health Sci. 2023; 23(1):23-36.

PMID: 37545919 PMC: 10398506. DOI: 10.4314/ahs.v23i1.4.


Antiviral Activity of Acetylsalicylic Acid against Bunyamwera Virus in Cell Culture.

Fernandez-Sanchez S, Ceron-Carrasco J, Risco C, de Castro I Viruses. 2023; 15(4).

PMID: 37112928 PMC: 10141918. DOI: 10.3390/v15040948.


A Systematic Review of Second-Line Treatments in Antiviral Resistant Strains of HSV-1, HSV-2, and VZV.

Lince K, DeMario V, Yang G, Tran R, Nguyen D, Sanderson J Cureus. 2023; 15(3):e35958.

PMID: 37041924 PMC: 10082683. DOI: 10.7759/cureus.35958.


References
1.
Baram-Pinto D, Shukla S, Perkas N, Gedanken A, Sarid R . Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate. Bioconjug Chem. 2010; 20(8):1497-502. DOI: 10.1021/bc900215b. View

2.
Cao J, Forrest J, Zhang X . A screen of the NIH Clinical Collection small molecule library identifies potential anti-coronavirus drugs. Antiviral Res. 2014; 114:1-10. PMC: 7113785. DOI: 10.1016/j.antiviral.2014.11.010. View

3.
Barre-Sinoussi F, Ross A, Delfraissy J . Past, present and future: 30 years of HIV research. Nat Rev Microbiol. 2013; 11(12):877-83. DOI: 10.1038/nrmicro3132. View

4.
Dyall J, Coleman C, Hart B, Venkataraman T, Holbrook M, Kindrachuk J . Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother. 2014; 58(8):4885-93. PMC: 4136000. DOI: 10.1128/AAC.03036-14. View

5.
Wong R, Balachandran A, Ostrowski M, Cochrane A . Digoxin suppresses HIV-1 replication by altering viral RNA processing. PLoS Pathog. 2013; 9(3):e1003241. PMC: 3610647. DOI: 10.1371/journal.ppat.1003241. View